Sumitomo Chemical India Limited — Investor Meet, 03-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Sumitomo Chemical India's earnings call highlighted financial results for the quarter and half-year ending September 30, 2025. Q2 revenue dipped to INR930 Cr (vs. INR988 Cr YoY) due to erratic rainfall, but H1 revenue grew 9% to INR1,987 Cr, with PAT up 11% to INR356 Cr, maintaining 43.1% gross margins. Management is optimistic for Rabi and notes global industry stabilization. New products (Excalia Max, Lentigo) show strong traction. Strategic priorities include significant Dahej manufacturing investments (initial INR250-300 Cr), strengthening farmer engagement, and making India a key testing hub for new molecules. The company pursues disciplined, margin-focused growth.